Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results

Sangamo Therapeutics (NASDAQ:SGMO) announced its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO traded up $0.03 on Monday, hitting $1.01. The company’s stock had a trading volume of 6,642,982 shares, compared to its average volume of 7,617,359. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The company has a market capitalization of $210.73 million, a price-to-earnings ratio of -1.35 and a beta of 1.49. The stock’s 50-day moving average is $1.10 and its two-hundred day moving average is $1.41.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SGMO shares. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Jefferies Financial Group dropped their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, January 27th. Truist Financial dropped their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company dropped their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $5.80.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.